BB:CYAD Celyad SA

Celyad SA, a biopharmaceutical company, focuses on engineered cell therapy treatments. It operates in two segments, Cardiology and Immuno-oncology. The company's lead product candidate in cardiovascular disease is C-Cure, an autologous cell therapy for the treatment of patients with ischemic heart failure. Its lead product candidate in oncology disease is CAR-T NKR-2, an autologous chimeric antigen receptor (CAR) for the treatment of cancer. In addition, the company's preclinical stage product candidates include NKp30, an activated receptor of NK cells; B7H6 therapies, which kills cancer cells; and CAR T-cell, an allogeneic T-cell platform. Further, it offers C-CATHez, a cell injection catheter; heart access sheaths; mitral valve neo-chordaes; and closure devices. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.This company has ADRs that trade in the U.S. as the symbol CYAD.

3.47 EUR
As of 01/14/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Belgium
Country of incorporation:  Belgium
IPO date:  07/04/2013
Stock exchange:    Nyse Euronext - Euronext
Exchange country:   Belgium
Market cap:   78,401,184 EUR
Current dividend yield:   0.00%
Sedol:      BBPLYF7

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy